RT Journal Article
T1 What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts
A1 Mucke, Johanna
A1 Alarcon-Riquelme, Marta
A1 Andersen, Jeanette
A1 Aringer, Martin
A1 Bombardieri, Stefano
A1 Brinks, Ralph
A1 Cervera, Ricard
A1 Chehab, Gamal
A1 Cornet, Alain
A1 Costedoat-Chalumeau, Nathalie
A1 Czirjak, Laszlo
A1 Doria, Andrea
A1 Fischer-Betz, Rebecca
A1 Furie, Richard A.
A1 Gatto, Mariele
A1 Houssiau, Frederic A.
A1 Ines, Luis
A1 Liang, Matthew H.
A1 Morand, Eric
A1 Mosca, Marta
A1 Maria Pego-Reigosa, Jose
A1 Rua-Figueroa, Inigo
A1 Ruiz-Irastorza, Guillermo
A1 Terrier, Benjamin
A1 Voss, Anne
A1 Schneider, Matthias
K1 lupus erythematosus
K1 systemic
K1 qualitative research
K1 outcome assessment
K1 health care
K1 Belimumab
K1 Erythematosus
AB Despite promising candidates for new therapeutic options in the treatment of systemic lupus erythematosus (SLE), many clinical trials have failed in the past few years. The disappointing results have been at least partly be attributed to trial designs. With the aim of stimulating new developments in SLE trial design, an international open space meeting was held on occasion of the European Lupus Meeting 2018 in Duesseldorf, Germany about 'What are the topics you care about for making trials in lupus more effective?'. The Open Space is a participant-driven technology, where the discussion topics and schedule are selected during the meeting by all participants and discussion rounds are led by the people attending encouraging active contributions. Eleven topics were selected for further discussion, of which 6 were voted to be more intensively discussed in two consecutive rounds. Major topics were the optimal handling of glucocorticoids in clinical trials, the improvement of outcome measures, reducing or controlling the placebo response and the identification of biomarkers and stratification parameters. Further, the importance of local and international networks was emphasised. By networking, collaborations are facilitated, patient recruitment is more efficient and treatment can be harmonised thus lead to more successful SLE trials. Further discussions are needed to substantiate the results and develop new trial designs.
PB Bmj publishing group
SN 2053-8790
YR 2021
FD 2021-01-01
LK https://hdl.handle.net/10668/28397
UL https://hdl.handle.net/10668/28397
LA en
DS RISalud
RD Apr 4, 2025